Alar PharmaceuticalsROCO:6785 52 Dividend Yield % is 0.21% as of Jul. 13, 2026, which is at its 10-year median of 0.21. GuruFocus rates ROCO:6785 with a GF Score™ of 52/100 and a GF Value™ of NT$90.64 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 516 Drug Manufacturers companies, Alar Pharmaceuticals ranks worse than 93.41% on this metric.
As of today (2026-07-13), the Trailing Annual Dividend Yield of Alar Pharmaceuticals is 0.21%.
Good Sign:
Alar Pharmaceuticals Inc stock Dividend Yield % is close to 1-year high.
The historical rank and industry rank for Alar Pharmaceuticals's Dividend Yield % or its related term are showing as below:
ROCO:6785'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.08 Med: 0.21 Max: 1.26
Current: 0.21
During the past 9 years, the highest Dividend Yield of Alar Pharmaceuticals was 1.26%. The lowest was 0.08%. And the median was 0.21%.
ROCO:6785's Dividend Yield % is ranked worse than 93.41% of 516
companies
in the Drug Manufacturers industry
Industry Median: 1.93
vs ROCO:6785: 0.21
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Alar Pharmaceuticals Dividend Yield % Related Terms
Alar Pharmaceuticals Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Alar Pharmaceuticals's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6785 vs ZTS, UTHR: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alar Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alar Pharmaceuticals Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alar Pharmaceuticals's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Alar Pharmaceuticals's Dividend Yield % falls into.
Alar Pharmaceuticals (ROCO:6785) has a Dividend Yield % of 0.21% as of Jul. 13, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Alar Pharmaceuticals and its competitors. This is near median its historical median of 0.21. Over the past decade, Alar Pharmaceuticals' Dividend Yield % has ranged from 0.08 to 1.26. According to the industry distribution chart, Alar Pharmaceuticals ranks #482 out of 516 companies in the Drug Manufacturers industry, placing it in the top 93.4%.
Is Alar Pharmaceuticals' Dividend Yield % too high?
Alar Pharmaceuticals' current Dividend Yield % of 0.21% is near median its 10-year median of 0.21. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 1.26. The Drug Manufacturers industry median Dividend Yield % is 1.93. Alar Pharmaceuticals' value of 0.21% is 89.1% below this industry median. Based on the distribution chart, Alar Pharmaceuticals ranks #482 out of 516 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alar Pharmaceuticals has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alar Pharmaceuticals' Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alar Pharmaceuticals ranks #482 out of 516 companies for Dividend Yield %. This places Alar Pharmaceuticals in the lower half of its industry. The industry median Dividend Yield % is 1.93. Alar Pharmaceuticals' value of 0.21% is 89.1% below this benchmark. Historically, Alar Pharmaceuticals' own Dividend Yield % has ranged from 0.08 to 1.26 over the past decade. While the company's 10-year median is 0.21 vs. the industry median of 1.93, Alar Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.93, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alar Pharmaceuticals's current Dividend Yield % of 0.21% is 89.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Alar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alar Pharmaceuticals's current Dividend Yield % is 0.21%, which is near median its own 10-year median of 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alar Pharmaceuticals (ROCO:6785) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$90.64, compared to a current price of NT$117.00 — trading 29.1% above its estimated fair value. The current Dividend Yield % is 0.21%, which is near median its 10-year median of 0.21 and 89.1% below the Drug Manufacturers industry median of 1.93. Alar Pharmaceuticals' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Alar Pharmaceuticals (ROCO:6785), the current Dividend Yield % is 0.21% as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?
Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be overvalued.
The current stock price of NT$117.00 is trading 29.1% above its estimated GF Value™ of NT$90.64.
GuruFocus considers Alar Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ROCO:6785:
Dividend Yield %: 0.21% (near median its 10-year median of 0.21)
GF Value™: NT$90.64 vs. price of NT$117.00 (29.1% above fair value)
Industry Position: 89.1% below the Drug Manufacturers median (#482 of 516)
No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
52GF Score
Get the complete analysis for ROCO:6785
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6785 has been successfully added to your 
